keyword
MENU ▼
Read by QxMD icon Read
search

meningococcal b vaccine

keyword
https://www.readbyqxmd.com/read/29337653/safety-and-immunogenicity-of-a-meningococcal-b-recombinant-vaccine-when-administered-with-routine-vaccines-to-healthy-infants-in-taiwan-a-phase-3-open-label-randomized-study
#1
Nan-Chang Chiu, Li-Min Huang, Arnold Willemsen, Chiranjiwi Bhusal, Ashwani Kumar Arora, Zenaida Reynoso Mojares, Daniela Toneatto
Neisseria meningitidis is associated with high mortality and morbidity in infants and children worldwide. This phase 3 study (NCT02173704) evaluated safety and immunogenicity of a 4-component serogroup B recombinant meningococcal vaccine (4CMenB) co-administered with routine vaccines in Taiwanese infants. In total, 225 healthy infants were randomized (2:1) to receive 4CMenB and routine vaccines (4CMenB+Routine) or routine vaccines only (Routine group) at 2, 4, 6 and 12 months of age. Routine vaccines were diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b, 13-valent pneumococcal, hepatitis B, measles-mumps-rubella and varicella vaccines...
January 16, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29336924/immunization-of-preterm-infants-with-gsk-s-hexavalent-combined-diphtheria-tetanus-acellular-pertussis-hepatitis-b-inactivated-poliovirus-haemophilus-influenzae-type-b-conjugate-vaccine-a-review-of-safety-and-immunogenicity
#2
Felix Omeñaca, Liliana Vázquez, Pilar Garcia-Corbeira, Narcisa Mesaros, Linda Hanssens, Jan Dolhain, Ivonne Puente Gómez, Johannes Liese, Markus Knuf
BACKGROUND: Infants with history of prematurity (<37 weeks gestation) and low birth weight (LBW, <2500 g) are at high risk of infection due to functional immaturity of normal physical and immunological defense mechanisms. Despite current recommendations that infants with history of prematurity/LBW should receive routine immunization according to the same schedule and chronological age as full-term infants, immunization is often delayed. METHODS: Here we summarize 10 clinical studies and 15 years of post-marketing safety surveillance of GSK's hexavalent vaccine (DTPa-HBV-IPV/Hib), a combined diphtheria-tetanus-acellular-pertussis-hepatitis-B-inactivated-poliovirus-Haemophilus influenzae-type-b (Hib) conjugate vaccine, when administered alone, or co-administered with pneumococcal conjugate, rotavirus, and meningococcal vaccines and respiratory syncytial virus IgG to infants with history of prematurity/LBW in clinical trials...
January 11, 2018: Vaccine
https://www.readbyqxmd.com/read/29329168/immune-responses-to-booster-vaccination-with-meningococcal-abcwy-vaccine-following-primary-vaccination-with-either-investigational-or-licensed-vaccines-a-phase-2-randomized-study
#3
Leszek Szenborn, Stan L Block, Teresa Jackowska, Ryszard Konior, Diego DʼAgostino, Igor Smolenov, Daniela Toneatto, Jo Anne Welsch
BACKGROUND: Current meningococcal prime-boost vaccination schedules include separate vaccines for serogroups ACWY and B. An investigational combined serogroups ABCWY vaccine (MenABCWY) was developed to protect against clinically important Neisseria meningitidis serogroups. METHODS: In this phase 2, randomized, observer-blind, extension study (NCT01272180), participants aged 10-25 years received 1 booster dose of MenABCWY vaccine at 24 months (M) post-primary series of either MenABCWY (2 doses), 4CMenB (2 doses) or MenACWY-CRM vaccine (1 dose)...
January 11, 2018: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/29301718/-immunisation-schedule-of-the-spanish-association-of-paediatrics-2018-recommendations
#4
David Moreno-Pérez, Francisco José Álvarez García, Javier Álvarez Aldeán, María José Cilleruelo Ortega, María Garcés Sánchez, Nuria García Sánchez, Ángel Hernández Merino, María Méndez Hernández, Manuel Merino Moína, Abián Montesdeoca Melián, Jesús Ruiz-Contreras
The Advisory Committee on Vaccines of the Spanish Association of Paediatrics annually publishes the immunisation schedule considered optimal for children resident in Spain, according to available evidence on current vaccines. Regarding funded immunisations, 2+1 strategy (2, 4, 11-12 months) with hexavalent (DTPa-IPV-Hib-HB) and 13-valent pneumococcal vaccines are recommended. Administration of the 6-year booster dose with DTPa is recommended, and a poliomyelitis dose for children who had received the 2+1 scheme, as well as Tdap vaccine for adolescents and pregnant women in every pregnancy between 27 and 32 weeks' gestation...
January 2018: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría (A.E.P.)
https://www.readbyqxmd.com/read/29287771/lower-antibody-functionality-in-middle-aged-adults-compared-to-adolescents-after-primary-meningococcal-vaccination-role-of-igm
#5
Marieke van der Heiden, Mariette B van Ravenhorst, Marjan Bogaard, Annemieke M H Boots, Guy A M Berbers, Anne-Marie Buisman
INTRODUCTION: Successful vaccination of elderly persons is often hampered by immunological ageing, leaving part of the elderly population vulnerable for infectious diseases. As an alternative, timely vaccinations might be administered at middle-age, before reaching old age. Studies evaluating the immunological fitness of middle-aged adults are warranted. In this study we compared the immunogenicity of a primary meningococcal vaccination in Dutch middle-aged adults with that in adolescents, in order to gain knowledge on the early signs of immune ageing...
December 26, 2017: Experimental Gerontology
https://www.readbyqxmd.com/read/29287682/development-of-an-fhbp-ctb-holotoxin-like-chimera-and-the-elicitation-of-bactericidal-antibodies-against-serogroup-b-neisseria-meningitidis
#6
Gregory A Price, Margaret C Bash
The Neisseria meningitidis factor H binding protein (FHbp) is an important virulence factor and vaccine antigen contained in both USA licensed serogroup B meningococcal vaccines. Recent studies in human factor H (hFH) transgenic mice suggest that hFH-FHbp interactions lower FHbp-elicited immunogenicity. To provide tools with which to characterize and potentially improve FHbp immunogenicity, we developed an FHbp-cholera holotoxin-like chimera vaccine expression system in Escherichia coli that utilizes cholera toxin B (CTB) as both a scaffold and adjuvant for FHbp...
December 26, 2017: Vaccine
https://www.readbyqxmd.com/read/29246475/estimating-primary-care-attendance-rates-for-fever-in-infants-after-meningococcal-b-vaccination-in-england-using-national-syndromic-surveillance-data
#7
Sally Harcourt, Roger A Morbey, Chris Bates, Helen Carter, Shamez N Ladhani, Simon de Lusignan, Gillian E Smith, Alex J Elliot
BACKGROUND: In September 2015, the United Kingdom became the first country to introduce the multicomponent group B meningococcal vaccine (4CMenB) into a national infant immunisation programme. In early clinical trials 51-61% of infants developed a fever when 4CMenB was administered with other routine vaccines. Whilst administration of prophylactic paracetamol is advised, up to 3% of parents may seek medical advice for fever following vaccination. We used research-level general practitioner consultations to identify any increase in attendances for all-cause fever in vaccine-eligible infants following 4CMenB introduction in England...
December 12, 2017: Vaccine
https://www.readbyqxmd.com/read/29236639/a-bivalent-meningococcal-b-vaccine-in-adolescents-and-young-adults
#8
RANDOMIZED CONTROLLED TRIAL
Lars Ostergaard, Timo Vesikari, Judith Absalon, Johannes Beeslaar, Brian J Ward, Shelly Senders, Joseph J Eiden, Kathrin U Jansen, Annaliesa S Anderson, Laura J York, Thomas R Jones, Shannon L Harris, Robert O'Neill, David Radley, Roger Maansson, Jean-Louis Prégaldien, John Ginis, Nina B Staerke, John L Perez
BACKGROUND: MenB-FHbp is a licensed meningococcal B vaccine targeting factor H-binding protein. Two phase 3 studies assessed the safety of the vaccine and its immunogenicity against diverse strains of group B meningococcus. METHODS: We randomly assigned 3596 adolescents (10 to 18 years of age) to receive MenB-FHbp or hepatitis A virus vaccine and saline and assigned 3304 young adults (18 to 25 years of age) to receive MenB-FHbp or saline at baseline, 2 months, and 6 months...
December 14, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29203096/meningococcal-disease-a-clinical-and-epidemiological-review
#9
REVIEW
Rodrigo Siqueira Batista, Andréia Patrícia Gomes, Jorge Luiz Dutra Gazineo, Paulo Sérgio Balbino Miguel, Luiz Alberto Santana, Lisa Oliveira, Mauro Geller
Meningococcal disease is the acute infection caused by Neisseria meningitidis, which has humans as the only natural host. The disease is widespread around the globe and is known for its epidemical potential and high rates of lethality and morbidity. The highest number of cases of the disease is registered in the semi-arid regions of sub-Saharan Africa. In Brazil, it is endemic with occasional outbreaks, epidemics and sporadic cases occurring throughout the year, especially in the winter. The major epidemics of the disease occurred in Brazil in the 70's caused by serogroups A and C...
November 2017: Asian Pacific Journal of Tropical Medicine
https://www.readbyqxmd.com/read/29202798/intention-to-vaccinate-universally-against-varicella-rotavirus-gastroenteritis-meningococcal-b-disease-and-seasonal-influenza-among-parents-in-the-netherlands-an-internet-survey
#10
Alies van Lier, José A Ferreira, Liesbeth Mollema, Elisabeth A M Sanders, Hester E de Melker
OBJECTIVE: For the decision-making process regarding introduction of new vaccines into the National Immunisation Programme (NIP), advance insight into the potential acceptance among the population is relevant. We studied the intention of parents to have their child vaccinated against four diseases not currently covered by the NIP in the Netherlands. The results on varicella have been published before; this article adds the results on vaccination against rotavirus gastroenteritis, meningococcal B disease, and seasonal influenza...
December 4, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/29183735/meningococcal-carriage-among-a-university-student-population-united-states-2015
#11
Lucy Breakwell, Melissa Whaley, Unab I Khan, Utpala Bandy, Nicole Alexander-Scott, Lynn Dupont, Cindy Vanner, How-Yi Chang, Jeni T Vuong, Stacey Martin, Jessica R MacNeil, Xin Wang, Sarah A Meyer
OBJECTIVES: Several outbreaks of serogroup B meningococcal disease have occurred among university students in recent years. In the setting of high coverage of the quadrivalent meningococcal conjugate vaccine and prior to widespread use of serogroup B meningococcal vaccines among adolescents, we conducted surveys to characterize the prevalence and molecular characteristics of meningococcal carriage among university students. METHODS: Two cross-sectional oropharyngeal carriage surveys were conducted among undergraduates at a Rhode Island university...
November 25, 2017: Vaccine
https://www.readbyqxmd.com/read/29176349/epidemiology-of-community-acquired-bacterial-meningitis
#12
Matthijs C Brouwer, Diederik van de Beek
PURPOSE OF REVIEW: The epidemiology of bacterial meningitis has been dynamic in the past 30 years following introduction of conjugated vaccines against Haemophilus influenzae type B, Streptococcus pneumoniae and Neisseria meningitidis. The purpose of this review is to describe recent developments in bacterial meningitis epidemiology. RECENT FINDINGS: The incidence of bacterial meningitis in Western countries (Finland, Netherlands, and the United States) gradually declined by 3-4% per year to 0...
February 2018: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/29170349/52%C3%A2-loop-mediated-isothermal-amplification-pcr-lamp-for-the-rapid-identification-of-invasive-meningococcal-disease-in-the-emergency-department
#13
Thomas Waterfield, Bethany Patenall, James McKenna, Derek Fairley
BACKGROUND: Despite successful vaccination programmes meningococcal disease (MD) remains the leading infectious cause of septicaemia and death in children in the UK and Ireland.1,2 The early diagnosis of MD significantly improves outcomes with reduced morbidity and mortality.1,2 The early stages of MD are often indistinguishable from a simple viral illness making an early positive diagnosis of MD difficult.1 Hibergene have developed a commercially available bedside Loop-mediated isothermal AMPlification PCR (LAMP-MD) test that is a highly sensitive 0...
December 2017: Emergency Medicine Journal: EMJ
https://www.readbyqxmd.com/read/29164681/urticarial-vasculitis-after-meningococcal-serogroup-b-vaccine-in-a-6-year-old-girl
#14
Virginia Velasco-Tamariz, Marta Prieto-Barrios, Fátima Tous-Romero, Sara Isabel Palencia-Pérez, Concepción Postigo-Llorente
The first vaccine that shows significant potential in providing broad coverage against serogroup B meningococcal disease has recently been approved. Because of its newness, potential adverse events need to be reported. Here we report a case of urticarial vasculitis, a rare disease in children, in probable relationship with the novel vaccine.
November 21, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/29152576/meningococcal-antigen-typing-system-mats-based-neisseria-meningitidis-serogroup-b-coverage-prediction-for-the-menb-4c-vaccine-in-the-united-states
#15
Gowrisankar Rajam, Maria Stella, Ellie Kim, Simon Paulos, Giuseppe Boccadifuoco, Laura Serino, George Carlone, Duccio Medini
Neisseria meningitidis is the most common cause of bacterial meningitis in children and young adults worldwide. A 4-component vaccine against N. meningitidis serogroup B (MenB) disease (MenB-4C [Bexsero]; GSK) combining factor H binding protein (fHBP), neisserial heparin binding protein (NHBA), neisserial adhesin A (NadA), and PorA-containing outer membrane vesicles was recently approved for use in the United States and other countries worldwide. Because the public health impact of MenB-4C in the United States is unclear, we used the meningococcal antigen typing system (MATS) to assess the strain coverage in a panel of strains representative of serogroup B (NmB) disease in the United States...
November 2017: MSphere
https://www.readbyqxmd.com/read/29136861/quality-by-design-approach-in-the-development-of-an-ultra-high-performance-liquid-chromatography-method-for-bexsero-meningococcal-group-b-vaccine
#16
Luca Nompari, Serena Orlandini, Benedetta Pasquini, Cristiana Campa, Michele Rovini, Massimo Del Bubba, Sandra Furlanetto
Bexsero is the first approved vaccine for active immunization of individuals from 2 months of age and older to prevent invasive disease caused by Neisseria meningitidis serogroup B. The active components of the vaccine are Neisseria Heparin Binding Antigen, factor H binding protein, Neisseria adhesin A, produced in Escherichia coli cells by recombinant DNA technology, and Outer Membrane Vesicles (expressing Porin A and Porin B), produced by fermentation of Neisseria meningitidis strain NZ98/254. All the Bexsero active components are adsorbed on aluminum hydroxide and the unadsorbed antigens content is a product critical quality attribute...
February 1, 2018: Talanta
https://www.readbyqxmd.com/read/29132992/measuring-the-timeliness-of-childhood-vaccinations-using-cohort-data-and-routine-health-records-to-evaluate-quality-of-immunisation-services
#17
Suzanne Walton, Mario Cortina-Borja, Carol Dezateux, Lucy J Griffiths, Karen Tingay, Ashley Akbari, Amrita Bandyopadhyay, Ronan A Lyons, Helen Bedford
BACKGROUND: To achieve full benefits of vaccination programmes, high uptake and timely receipt of vaccinations are required. OBJECTIVES: To examine uptake and timeliness of infant and pre-school booster vaccines using cohort study data linked to health records. METHODS: We included 1782 children, born between 2000 and 2001, participating in the Millennium Cohort Study and resident in Wales, whose parents gave consent for linkage to National Community Child Health Database records at the age seven year contact...
November 10, 2017: Vaccine
https://www.readbyqxmd.com/read/29128379/active-sms-based-influenza-vaccine-safety-surveillance-in-australian-children
#18
Alexis Pillsbury, Helen Quinn, Patrick Cashman, Alan Leeb, Kristine Macartney
INTRODUCTION: Australia's novel, active surveillance system, AusVaxSafety, monitors the post-market safety of vaccines in near real time. We analysed cumulative surveillance data for children aged 6 months to 4 years who received seasonal influenza vaccine in 2015 and/or 2016 to determine: adverse event following immunisation (AEFI) rates by vaccine brand, age and concomitant vaccine administration. METHODS: Parent/carer reports of AEFI occurring within 3 days of their child receiving an influenza vaccine in sentinel immunisation clinics were solicited by Short Message Service (SMS) and/or email-based survey...
November 8, 2017: Vaccine
https://www.readbyqxmd.com/read/29126310/current-epidemiology-and-trends-in-meningococcal-disease-united-states-1996-2015
#19
Jessica R MacNeil, Amy E Blain, Xin Wang, Amanda C Cohn
Background: In 2005, meningococcal conjugate vaccine (MenACWY) was recommended for routine use among adolescents aged 11-18 years. This report describes the epidemiologic features of meningococcal disease and trends in meningococcal disease incidence following MenACWY introduction in the United States. Methods: Incidence rates and case-fatality ratios by age group and serogroup during 2006-2015 were calculated using data from the National Notifiable Diseases Surveillance System (NNDSS); changes in incidence during this time were evaluated...
November 8, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29116892/lessons-from-the-meningitis-vaccine-project
#20
F Marc LaForce, Mamoudou Djingarey, Simonetta Viviani, Marie-Pierre Preziosi
From 2001 to 2017 the Meningitis Vaccine Project (MVP), a Gates Foundation funded partnership between PATH and the World Health Organization (WHO), successfully developed, tested, licensed, and introduced an affordable new Group A meningococcal conjugate vaccine, MenAfriVac(®), in sub-Saharan Africa. The vaccine was well received, and from 2010 to 2016, over 260 million Africans have received a dose of the vaccine in campaigns largely directed at 1-29-year olds. The public health impact has been dramatic with the elimination of Group A meningococcal infections wherever the vaccine has been used at public health scale...
November 8, 2017: Viral Immunology
keyword
keyword
61786
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"